The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy

Publisher： Karger

E-ISSN： 1421-9794|60|2|107-111

ISSN： 0009-3157

Source： Chemotherapy, Vol.60, Iss.2, 2015-02, pp. : 107-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

By Bersanelli Melissa   Buti Sebastiano   Camisa Roberta   Brighenti Matteo   Lazzarelli Silvia   Mazza Giancarlo   Passalacqua Rodolfo  

Cancers, Vol. 6, Iss. 4, 2014-09 ,pp. : 2035-2048

MDPI

Access to resources Recommend Favorite

Phase II Trial of Biweekly Chemotherapy with Docetaxel and Cisplatin in High-Risk Patients with Unresectable Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-10 ,pp. : 159-166

Karger

Access to resources Recommend Favorite

The Value of Tumor Markers in Evaluating Chemotherapy Response and Prognosis in Chinese Patients with Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 56, Iss. 6, 2010-11 ,pp. : 417-423

Karger

Access to resources Recommend Favorite

Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer

By Li Yanxia   Song Zhendong   Jin Yue   Tang Zeyao   Kang Jian   Ma Xiaodong  

Molecules, Vol. 21, Iss. 11, 2016-11 ,pp. : 1462-1462

MDPI

Access to resources Recommend Favorite

Gemcitabine Plus Vinorelbine as the Second-Line Treatment and Beyond in Elderly Patients with Platinum-Pretreated Advanced Non-Small Cell Lung Cancer

By  

Chemotherapy, Vol. 60, Iss. 4, 2015-04 ,pp. : 267-273

Karger

Access to resources Recommend Favorite